Erectile Dysfunction: Treatment

  • John P. Mulhall
  • Peter J. Stahl
  • Doron S. Stember


The willingness to pursue treatment for ­erectile dysfunction (ED) is dependent on many factors but associated patient bother and distress is a key factor. Other relevant factors to consider include the presence of contraindications to therapy, the absence of partner, lack of willingness of partner to participate in sexual relations, and cost of treatment. As outlined in the other ED algorithms, some patients will have undergone extended evaluation and others will have forgone further assessment. While 50 % of men over 40 years of age have some degree of ED, less than 10 % ever seek treatment, presumably because many of them are not bothered by the ED and are capable of having satisfactory sexual relations despite their ED.


Nitric Oxide Vacuum Device Cardiac Reserve Venous Leak Cavernosal Smooth Muscle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Reading

  1. Corona G, Mondaini N, Ungar A, Razzoli E, Rossi A, Fusco F. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med. 2011;8(12):3418–32.PubMedCrossRefGoogle Scholar
  2. Garcia JA, Sanchez PE, Fraile C, Escovar P. Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone. Andrologia. 2011;43(5):293–6.PubMedCrossRefGoogle Scholar
  3. Leungwattanakij S, Flynn Jr V, Hellstrom WJ. Intracavernosal injection and intraurethral therapy for erectile dysfunction. Urol Clin North Am. 2001;28(2):343–54.PubMedCrossRefGoogle Scholar
  4. Melnik T, Soares BG, Nasello AG. The effectiveness of psychological interventions for the treatment of erectile dysfunction: systematic review and meta-analysis, including comparisons to sildenafil treatment, intracavernosal injection, and vacuum devices. J Sex Med. 2008;5(11):2562–74.PubMedCrossRefGoogle Scholar
  5. Montague DK, Barada JH, Belker AM, et al. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. The American Urological Association. J Urol. 1996;156(6):2007–11.PubMedCrossRefGoogle Scholar
  6. Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, Lue TF, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7(11):3572–88.PubMedCrossRefGoogle Scholar
  7. Mulhall JP, Montorsi F. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol. 2006;49(1):30–7.PubMedCrossRefGoogle Scholar
  8. Mulhall JP, Althof SE, Brock GB, Goldstein I, Junemann KP, Kirby M. Erectile dysfunction: monitoring response to treatment in clinical practice–recommendations of an international study panel. J Sex Med. 2007;4(2):448–64.PubMedCrossRefGoogle Scholar
  9. Qaseem A, Snow V, Denberg TD, et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2009;151(9):639–49.PubMedCrossRefGoogle Scholar
  10. Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151(9):650–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • John P. Mulhall
    • 1
  • Peter J. Stahl
    • 2
  • Doron S. Stember
    • 3
  1. 1.Sexual and Reprodictive Medicine Program Department of Surgery Division of Urology, Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of UrologyColumbia University College of Physicians & SurgeonsNew YorkUSA
  3. 3.Department of UrologyBeth Israel Medical Center Albert Einstein College of Medicine of Yeshiva UniversityNew YorkUSA

Personalised recommendations